Home › Funds › Evolutionary Tree Capital Management, LLC › ARWR
Evolutionary Tree Capital Management, LLC position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Evolutionary Tree Capital Management, LLC reported holding 19,142 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 2.32% of its reported portfolio and ranking #21 among its reported holdings. Evolutionary Tree Capital Management, LLC has disclosed ARWR holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Evolutionary Tree Capital Management, LLC's ARWR position evolved
Evolutionary Tree Capital Management, LLC first disclosed a stake in ARWR in Q3 2023 at 51,266 shares (US$1.4M). The position peaked in Q4 2023 at 51,687 shares, worth US$1.6M. Across 5 filings, Evolutionary Tree Capital Management, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 19,142 shares valued at US$1.3M — an increase of 4,774 shares quarter over quarter.. Notable position changes include a 33% increase in Q3 2026 (shares fell 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 51.27K | $1.38M | New |
| Q4 2023 | 51.69K | $1.58M | Add |
| Q1 2024 | 44.90K | $1.28M | Reduce |
| Q2 2026 | 14.37K | $1.17M | New |
| Q3 2026 | 19.14K | $1.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 43 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 2.29M sh · $149.91M · Q3 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
More on Evolutionary Tree Capital Management, LLC
FAQ
How long has Evolutionary Tree Capital Management, LLC held ARWR?
Evolutionary Tree Capital Management, LLC has disclosed ARWR holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
What is Evolutionary Tree Capital Management, LLC's current position in ARWR?
As of Q3 2026, Evolutionary Tree Capital Management, LLC holds 19.14K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $1.25M, representing 2.32% of its reported portfolio and ranking #21.
Has Evolutionary Tree Capital Management, LLC been buying or selling ARWR?
In the latest 13F filing (Q3 2026), Evolutionary Tree Capital Management, LLC increased its position in ARWR. The position peaked in Q4 2023 at 51.69K shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.